Why this topic matters GLP-1 receptor agonists including compounded semaglutide and tirzepatide are reshaping how clinicians approach metabolic weight management
Color development was performed using DAB working solution for 10 min at room temperature and terminated by rinsing with ddHO
The FDA approves the active ingredient itself but does not individually approve each compounded formulation
[1] Additionally, the label cautions that tirzepatide may reduce the exposure of oral contraceptives taken concomitantly, particularly after initiation and dose escalation, potentially requiring alternative contraceptive methods
Concurrently, Structure Therapeutics is advancing an APJ-targeting molecule into Phase 2 evaluation for obesity, suggesting that the target remains of clinical interest when candidate molecules are appropriately selected
Currently, the only licensed GLP-1 tablet for weight loss in the UK is the Wegovy pill , which contains semaglutide